Brought to you by 
Gyrus-ENT to sell Genzyme Biosurgery products
04 Oct 2001
Executive Summary
Gyrus-ENT signed a five-year agreement with Genzyme Biosurgery giving it exclusive distribution rights to two of Genzyme's hyaluronic acid surgical products--Sepragel and Seprapack--plus their respective stents.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gyrus-ENT to sell Genzyme Biosurgery products
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice